aTYR PHARMA INC
No SEC Form 4 filings for $ATYR in the last 30 days.
See all $ATYR insider activity →aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “ Agreement ”) is made and entered into as of July 30, 2026 (“ Execution Date ”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of
SCHIMMEL PAUL purchased 100,000 indirectly-held shares of aTYR PHARMA INC (ATYR) at $0.50 on 2026-05-27.
Over the past 7 days, alphai's AI scored 1 news story mentioning ATYR (aTYR PHARMA INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ATYR coverage spans financial news, earnings and corporate actions.
The restructuring and FDA protocol-feedback timeline are near-term catalysts for ATYR’s cash burn expectations and Phase 3 execution risk.
Termination shifts development and commercialization rights for the Reversion Product (efzofitimod) toward aTyr, with regulatory and data handover mechanics.
The filing signals insider buying interest, but it is small and indirect, with no 10b5-1 plan disclosed.
Atyr Pharma Inc (ATYR) exhibits weak financial health characterized by low profitability and negative cash flow, despite maintaining liquidity and low leverage. The bearish sentiment from recent financial statements suggests caution for traders.
The lawsuit and investor call for action could introduce short-term volatility in ATYR stock. The legal proceedings might negatively impact investor confidence if the case is perceived as significant.
alphai scores every news story that mentions ATYR with an AI model for sentiment and relevance, and aggregates insider trades from aTYR PHARMA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod
4 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. EX-99.1 2 atyr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “ Agreement ”) is made and entered into as of July 30, 2026 (“ Execution Date ”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of
6 min readSCHIMMEL PAUL purchased 100,000 indirectly-held shares of aTYR PHARMA INC (ATYR) at $0.50 on 2026-05-27.
2 min readThis article provides a detailed financial overview of Atyr Pharma Inc (ATYR), including its income statement, balance sheet, and cash flow statement, along with key financial ratios. It highlights the company's financial health signals, annual and quarterly metrics, and frequently asked questions about its performance. The analysis indicates weak overall financial health with low profitability and negative cash flow, despite strong liquidity and low leverage.
3 min readSAN FRANCISCO, Nov. 27, 2025 ( GLOBE NEWSWIRE ) -- Global plaintiffs' rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. ( NASDAQ:ATYR ) .
2 min readLOS ANGELES, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
3 min readNEW YORK, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. ( NASDAQ:ATYR ) , Marex Group PLC ( NASDAQ:MRX ) , Cepton, Inc. ...
2 min readNEW YORK, Nov. 23, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. ( NASDAQ:ATYR ) between January 16, 2025 and September 12, 2025, both dates inclusive ( the "Class Period" ) , of the important ...
3 min readBENSALEM, Pa., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
3 min readFaruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
2 min read
